CLLS
Sign in
Cellectis SA
Save
124.72M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Cellectis S. A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants.
Similar securities
Based on sector and market capitalization
Report issue